PAPER Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, Green KN
SEARCH RESULTS
331008 RESULTS
PAPER Dixon RA, de Frias CM
Cognitively elite, cognitively normal, and cognitively impaired aging: neurocognitive status and stability moderate memory performance.
J Clin Exp Neuropsychol. 2014;36(4):418-30. Epub 2014 Apr 17 PubMed: 24742143PAPER Burbulla LF, Fitzgerald JC, Stegen K, Westermeier J, Thost AK, Kato H, Mokranjac D, Sauerwald J, Martins LM, Woitalla D, Rapaport D, Riess O, Proikas-Cezanne T, Rasse TM, Krüger R
Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1.
Cell Death Dis. 2014 Apr 17;5:e1180. PubMed: 24743735PAPER McLaughlin NC, Piryatinsky I, Epstein-Lubow G, Marino L, Friedman JH
Neuropsychiatric symptoms in an inpatient Parkinson's disease sample.
Parkinsons Dis. 2014;2014:420240. Epub 2014 Mar 12 PubMed: 24744956PAPER Morley JF, Pawlowski SM, Kesari A, Maina I, Pantelyat A, Duda JE
Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.
Parkinsonism Relat Disord. 2014 Jul;20(7):738-42. Epub 2014 Apr 1 PubMed: 24742370Guna Rajagopal
Janssen Research and DevelopmentSpring House, United States
Olav Andersen on Could Bolstering the Retromer Thwart Alzheimer’s?
COMMENT The paper by Mecozzi et al. elegantly demonstrates how a small drug, R55, is able to stabilize the retromer complex, enabling enhanced neuronal transport of APP (and sorLA) out of early endosomal compartments thereby escaping amyloidogenic processing. The
Matthew M J Farrer on Could Bolstering the Retromer Thwart Alzheimer’s?
COMMENT This study raises some intriguing possibilities. Loss of retromer expression has long been noted in AD, with consequent effects on APP processing and Aβ production. However, retromer recycling appears as a nexus for parkinsonism and dementia. Deficits in
Sam Gandy on Could Bolstering the Retromer Thwart Alzheimer’s?
COMMENT My reaction is that the new pro-retromer drug is brilliant and essential, and at the very least, we have a terrific new tool for cell biology at the bench. In contemplating its use in treating or preventing AD, there are some caveats that tend to keep me
James J. Lah on Could Bolstering the Retromer Thwart Alzheimer’s?
COMMENT Scott Small, Dagmar Ringe, Greg Petsko, and their colleagues are to be congratulated on a beautiful piece of science. This paper represents the combination of expert structural biology and AD cell biology to produce simultaneous advances in both arenas. T
Could Bolstering the Retromer Thwart Alzheimer’s?
RESEARCH NEWS 2014-04-20 Research News A potential Alzheimer’s treatment aims to whisk the amyloid precursor protein (APP) out of harm’s way to prevent it from generating Aβ. The small molecule fortifies the retromer, a large protein conglomerate that ferries APP out of endosomes
Carmen Morales
United States
Kelvin Luk, Laura Volpicelli-Daley on Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.
COMMENT We were happy to see that the authors were able to recapitulate formation of α-synuclein Lewy body and Lewy Neurite-like inclusions by intracranially injecting synthetic fibrils made from recombinant protein into the hippocampus and cortex of both non-tra
Jeannie Chin
Thomas Jefferson University
Debbie Morrison
Avondale, United States
Current Filters
No filters selected